货号 | FV678016 |
---|---|
品牌 | abinScience |
种属反应性 | Cat |
应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
宿主 | Felinized |
同种型 | IgG1-kappa |
表达系统 | Mammalian Cells |
克隆类型 | Monoclonal |
靶标 | IL-31, Interleukin-31, IL31 |
内毒素水平 | Please contact the lab for this information. |
纯度 | >95% purity as determined by SDS-PAGE. |
纯化方式 | Protein A/G purified from cell culture supernatant. |
Accession号 | A0A2I2UKP7 |
状态 | Liquid |
保存溶液 | 0.01M PBS, pH 7.4. |
稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
别名 | ZTS-00521505, 2171034-71-0 |
背景 | Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells. • The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037 • IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760 • Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401 • A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353 • Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036 • Nemolizumab: First Approval., PMID:35834124 • Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249 • The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566 • Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098 • Targeting Interleukin-31 in Prurigo., PMID:37888922 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Dovanvetmab.
24小时产品查询
扫一扫关注我们
专属渠道经理